ResMed Inc (RMD) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
ResMed Inc stock (RMD) is currently trading at $225.99. ResMed Inc PE ratio is 22.38. ResMed Inc PS ratio (Price-to-Sales) is 6.11. Analyst consensus price target for RMD is $296.87. WallStSmart rates RMD as Moderate Buy.
- RMD PE ratio analysis and historical PE chart
- RMD PS ratio (Price-to-Sales) history and trend
- RMD intrinsic value — DCF, Graham Number, EPV models
- RMD stock price prediction 2025 2026 2027 2028 2029 2030
- RMD fair value vs current price
- RMD insider transactions and insider buying
- Is RMD undervalued or overvalued?
- ResMed Inc financial analysis — revenue, earnings, cash flow
- RMD Piotroski F-Score and Altman Z-Score
- RMD analyst price target and Smart Rating
ResMed Inc
📊 No data available
Try selecting a different time range
RMD Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · ResMed Inc (RMD)
RMD is trading near its Graham intrinsic value of $303.00, suggesting the stock is reasonably priced at current levels.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
ResMed Inc (RMD) · 10 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in market cap, peg ratio, return on equity. Concerns around price/book. Overall metrics suggest strong investment potential with favorable risk/reward.
ResMed Inc (RMD) Key Strengths (6)
Every $100 of shareholder equity generates $26 in profit
Keeps $35 of every $100 in revenue after operating costs
Keeps $28 of every $100 in revenue as net profit
Large-cap company with substantial market presence
Good growth relative to its price
68.61% held by institutions, strong professional interest
Supporting Valuation Data
ResMed Inc (RMD) Areas to Watch (4)
Very expensive at 5.2x book value
Premium valuation at 6.1x annual revenue
Solid revenue growth at 11.00% per year
Solid earnings growth at 14.50%
Supporting Valuation Data
ResMed Inc (RMD) Detailed Analysis Report
Overall Assessment
This company scores 70/100 in our Smart Analysis, earning a B grade. Out of 10 metrics analyzed, 6 register as strengths (avg 9.2/10) while 4 fall into concern territory (avg 4.5/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Return on Equity, Operating Margin, Profit Margin. Valuation metrics including PEG Ratio (1.39) suggest the stock is attractively priced. Profitability is solid with Return on Equity at 25.70%, Operating Margin at 35.20%, Profit Margin at 27.50%.
The Bear Case
The primary concerns are Price/Book, Price/Sales, Revenue Growth. Some valuation metrics including Price/Sales (6.11), Price/Book (5.21) suggest expensive pricing. Growth concerns include Revenue Growth at 11.00%, EPS Growth at 14.50%, which may limit upside.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Price/Book improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 25.70% currently healthy but needing to be sustained. Third, growth sustainability, with Revenue Growth at 11.00% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a moderate risk investment. The weight of evidence leans positive, with more strengths than concerns. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
The combination of Return on Equity and Operating Margin makes a compelling case at current levels. The key risk is Price/Book, but the overall fundamental picture is positive with a clear path to maintaining or improving the current B grade.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
WallStSmart Analysis Synopsis
Data-driven financial summary for ResMed Inc (RMD) · HEALTHCARE › MEDICAL INSTRUMENTS & SUPPLIES
The Big Picture
ResMed Inc is a mature, profitable business with steady cash generation. Revenue reached 5.4B with 11% growth year-over-year. Profit margins are strong at 27.5%, reflecting pricing power and operational efficiency.
Key Findings
ROE of 2570.0% means the company generates strong returns on shareholder equity. Above 20% is considered top-tier.
Profit margin of 27.5% and operating margin of 35.2% demonstrate strong pricing power and operational efficiency.
What to Watch Next
Sector dynamics: monitor MEDICAL INSTRUMENTS & SUPPLIES industry trends, competitive moves, and regulatory changes that could impact ResMed Inc.
Bottom Line
ResMed Inc is a well-established business delivering consistent profitability with 27.5% margins. The growth phase may be slowing, but strong cash generation and operational efficiency make it suitable for investors seeking reliability over excitement.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(17 last 3 months)
| Insider | Type | Shares |
|---|---|---|
FARRELL, PETER C Director | Sell | -2,000 |
| Insider | Type | Shares |
|---|---|---|
SANDERCOCK, BRETT Chief Financial Officer | Sell | -1,000 |
| Insider | Type | Shares |
|---|---|---|
SANDERCOCK, BRETT Chief Financial Officer | Sell | -1,000 |
Data sourced from SEC Form 4 filings
Last updated: 8:39:40 AM
About ResMed Inc(RMD)
NYSE
HEALTHCARE
MEDICAL INSTRUMENTS & SUPPLIES
USA
ResMed is a San Diego, California-based medical equipment company. It primarily provides cloud-connectable medical devices for the treatment of sleep apnea (such as CPAP devices and masks), chronic obstructive pulmonary disease (COPD), and other respiratory conditions.